Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Evidence synthesis

Draft synthesis: Clinical evidence for growth-hormone secretagogues supplied for research

Consultation on the draft of this scoping review, which registers the question: What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?

Document identifier
CEI-CP-108
Series
Public comment period
Version
1.0
Published
13 Jan 2026
Last reviewed
13 Jan 2026
Next review
13 Jan 2027
Identifier
10.71829/cei.cp.108
Certainty
Not rated
Cycle
2025 Q4
Window
31 Oct 2025 – 12 Dec 2025
Status
Closed
Submissions
9

§1Consultation and window

§1.1Window

Opened
31 October 2025
Closed
12 December 2025
Duration
42 days
Status
Closed — the disposition is published
Document under consultation
Synthesis: Clinical evidence for growth-hormone secretagogues supplied for…
Submissions received
9

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the very low certainty rating for the anchor outcome correctly drawn from the contributing evidence?
  2. Is any eligible study missing from the included set, and is any included study ineligible under the registered criteria?
  3. Are the limitations recorded in the abstract sufficient, and is any material limitation omitted?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

Amendments arising were applied and are recorded in the review's amendment log, each traceable to a numbered submission.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.